Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma

Learn more about:
Related Clinical Trial
Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY Recurrence After Whipple’s (RAW): Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Head Malignancy Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care Prospective Evaluation of Biliary Tissue Sampling With ERCP Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture Liver Cancer Registry Platform Target Rare Cancer Knowledge Neoadjuvant Therapy in Biliary Adenocarcinoma BOLD-100 in Combination With FOLFOX for the Treatment of Advanced, Solid Tumours the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Efficacy of Fistulotomy for Biliary Cannulation A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Etomidate vs. Midazolam for Sedation During ERCP Loop-tipped Guidewire in Selective Biliary Cannulation Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm BKM120 in Cancers With PIK3CA Activating Mutations A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT PTFE Stents for Treatment of Malignant Biliary Strictures Irreversible Electroporation of Unresectable Liver Tumors Personal Resilience Empowerment Program Study Radiofrequency Ablation for Biliopancreatic Malignancy Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer In Vitro Models of Liver and Pancreatic Cancer Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Evaluation of Stereotactic Radiosurgery For Liver Malignancies Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD Margin Status After Pancreaticoduodenectomy for Cancer A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer A Study of TRK-950 in Patients With Advanced Solid Tumors Combined HCC-MFCCC Proton Therapy and Bevacizumab for Primary Liver Tumors Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases Fluorescence QRH-882260 Peptide Imaging in the Bile Duct A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer MRCP Diagnoses EHCC Better When Combined DWI Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Comparison of Biliary Forceps Biopsy and Brush Cytology Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Endobiliary RFA for Unresectable Malignant Biliary Strictures A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Clinical Effect and Safety of PDT and RFA for Unresectable EHCC Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma Trial of IRE in Cholangiocarcinoma Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer S-1 in Combination With Abraxane in Treating Cholangiocarcinoma Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol Study of Pembrolizumab and Olaparib in Bile Duct Cancer Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma ncRNAs in Exosomes of Cholangiocarcinoma Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma

Brief Title

Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma

Official Title

Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma

Brief Summary

      Background:

      Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts. People with CCA have few
      treatment options and poor survival. Researchers want to see if a new drug can stop or slow
      CCA growth.

      Objective:

      To find the safest and most effective dose of tivozanib to treat CCA and learn its overall
      response rate.

      Eligibility:

      Adults ages 18 and older with CCA not removable with surgery and have been treated with at
      least one type of chemotherapy.

      Design:

      Participants will be screened with the following:

        -  Medical history

        -  Physical exam

        -  Assessment of their ability to do daily activities

        -  Medicine review

        -  Blood tests, including thyroid function tests

        -  Urine tests

        -  Electrocardiogram, to check heart function

        -  Pregnancy test, if needed

        -  Tumor biopsy, if needed

        -  Computed tomography scans

        -  Magnetic resonance imaging, if needed

      Some screening tests may be repeated during the study.

      Participants will be asked to enroll in protocol #13C0176. This will allow any remaining
      tumor or blood samples to be used in future research.

      Participants will take tivozanib by mouth, once a day for 21 days per cycle or every other
      day per cycle. Each cycle is 28 days. They can take the drug until they have bad side
      effects, their CCA gets worse, or if they become pregnant. They will record their blood
      pressure twice daily at home. They will also keep a medication diary of each dose of
      tivozanib they take and any side effects.

      Participants will have study visits before starting each new cycle and every 8 weeks. They
      will also have a follow-up visit 30 days after treatment ends at NIH, or if they are unable
      to come to NIH by phone, videocall, or other NIH-approved platform. Then they will be
      contacted 6 and 12 months later, and then once a year.
    

Detailed Description

      Background:

      Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy that remains a clinical
      challenge with limited treatment options and poor survival. Combination chemotherapy with
      gemcitabine and cisplatin is the most validated first-line treatment, but the response rate
      approaches only 22% and median progression free survival is 8 months.

      Cytoplasmic accumulation of the nuclear export protein exportin 7, XPO7, portends poor
      outcomes for patients with cholangiocarcinoma. Using pre-clinical models, we established XPO7
      as an oncogenic driver in CCA cells and determined that this biology is driven by the
      interaction between XPO7 and a hitherto incompletely studied kinase, Ste-20 like kinase
      (SLK).

      XPO7 binds to and promotes cytoplasmic localization and stabilization of SLK, which in turn
      activates oncogenic AKT signaling. Targeting SLK expression via short hairpin RNA abrogates
      tumor formation in 3D culture and mice models, and leads to robust inhibition of AKT Ser 473
      phosphorylation, establishing SLK as a novel, bona fide target in cholangiocarcinoma.

      The pan-vascular endothelial growth factor receptor (VEGFR) inhibitor tivozanib, which also
      demonstrated activity against SLK in our in vitro screen, reduced AKT phosphorylation and
      abrogated growth of CCA tumorspheres and in a murine xenograft model. Additionally, we
      evaluated tivozanib in our ex vivo tumor platform using a liver metastasis from a patient
      with XPO7-expressing cholangiocarcinoma and documented effective tumor cell degeneration and
      death.

      As reliable, molecular-targeted regimens either for first- or second-line therapy for
      cholangiocarcinoma have remained elusive, these results support evaluation of tivozanib as a
      treatment option for patients with cholangiocarcinoma.

      Objectives:

      Phase I: To determine safety and establish the recommended Phase II dose (RP2D) of tivozanib
      in patients with cholangiocarcinoma who were previously treated with first-line chemotherapy.

      Phase II: To determine the overall response rate (RECIST) of tivozanib in patients with
      cholangiocarcinoma who were previously treated with first-line therapy.

      Eligibility:

      Patients with histologically or cytologically confirmed cholangiocarcinoma not amenable to
      resection

      Previous treatment with 1st line chemotherapy

      Age >= 18 years of age

      ECOG performance status of <=1

      Preserved hepatic function

      Adequate organ and marrow function

      Life expectancy >= 3 months

      Design:

      Open-label, single-center, non-randomized Phase I/II study

      Trial will begin with enrollment in a Phase I two dose-level, intra-patient dose escalation
      and possible dose de-escalation phase to determine safety and RP2D, followed by a Simon
      minimax two-stage Phase II trial design to determine efficacy.

      Treatment is in cycles of 28 days, 3 weeks on, 1 week off (except for patients in DL-1, with
      every other day dosing). Treatment evaluations for efficacy will be every 2 months (8 weeks).

      Accrual ceiling will be set at 30 patients
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Phase II: Determine the overall response rate by RECIST of tivozanib in patients with cholangiocarcinoma who were previously treated with first-line therapy.

Secondary Outcome

 Evaluate overall survival (OS) in patients with cholangiocarcinoma treated with tivozanib

Condition

Cholangiocarcinoma

Intervention

Tivozanib

Study Arms / Comparison Groups

 1/ Phase I
Description:  Tivozanib, P.O. daily at 1.0 mg (given on Days 1-21 of every 28-day cycle) with intra-patient escalation to 1.5 mg daily (given on Days 1-21 of every 28-day cycle) and possible dose de-escalation to 1.0 mg every other day (without interruption for a 28-day cycle) if needed to determine RP2D

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

30

Start Date

January 27, 2021

Completion Date

December 31, 2024

Primary Completion Date

December 31, 2023

Eligibility Criteria

        -  INCLUSION CRITERIA:

               1. Patients with histologically or cytologically confirmed cholangiocarcinoma by the
                  NCI Laboratory of Pathology. Archival tumor sample may be used but if archival
                  tissue is not available or is not adequate, tissue biopsy will be required.

               2. Patients must have cholangiocarcinoma that is not amenable to resection.

               3. Patients must have had prior treatment with 1st line chemotherapy.

               4. Disease must be measurable by Response Evaluation Criteria in Solid Tumors
                  (RECIST) criteria Version 1.1.

               5. Age >=18 years.

                  NOTE: Because no dosing or adverse event data are currently available on the use
                  of tivozanib in subjects < 18 years of age, children are excluded from this
                  study, but may be eligible for future pediatric trials.

               6. ECOG performance status <= 1

               7. If the patient has liver disease; Child Pugh Class A.

               8. Adequate organ and marrow function as defined below:

                    -  Hemoglobin >= 9.0 g/dL

                    -  Absolute neutrophil count >= 1,000/mcL

                    -  Platelets >= 75,000/mcL

                    -  Total bilirubin <= 2 X institutional upper limit of normal (ULN)

                    -  AST(SGOT)/ALT(SGPT) <= 5 X institutional ULN

                    -  Creatinine clearance >= 60 mL/min/1.73 m^2 calculated by calculated using
                       eGRF in the clinical lab

                    -  Serum Albumin (g/L) > 35

                    -  Alkaline phosphatase** <= 2.5 x ULN

                       **unless bony metastases present

                    -  INR < 1.7

               9. Negative serum or urine pregnancy test at screening for women of childbearing
                  potential (WOCBP).

                  NOTE: WOCBP is defined as any female who has experienced menarche and who has not
                  undergone successful surgical sterilization or who is not postmenopausal. WOCBP
                  must have a negative pregnancy test (HCG blood or urine) during screening.

              10. Women of child-bearing potential and men must agree to use adequate contraception
                  (hormonal or barrier method of birth control; abstinence) prior to study entry,
                  for the duration of study participation, and 1 month after completion of
                  treatment.

              11. Ability of subject to understand and the willingness to sign a written informed
                  consent document.

              12. Ability and willingness to co-enroll on the tissue collection protocol 13C0176,
                  "Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or
                  Surgical Resection of Solid Tumors".

        EXCLUSION CRITERIA:

          1. Chemotherapy, small molecule or radiation therapy within 3 weeks prior to
             administration of first dose of study drug.

          2. Prior treatment with Tivozanib.

          3. Any history of elevations of both total serum bilirubin > 2X ULN AND AST and/or ALT >
             3X ULN, unless related to common bile duct obstruction and treated adequately with a
             stent.

          4. History of hepatic encephalopathy within past 12 months or requirement for medications
             to prevent or control encephalopathy (e.g., no lactulose, rifaximin, etc. if used for
             purposes of hepatic encephalopathy).

          5. Inadequate recovery from any prior surgical procedure or major surgical procedure
             within 4 weeks prior to administration of first dose of study drug.

          6. Patients with previous malignant disease other than the target malignancy within the
             last 3 years with the exception of basal or squamous cell carcinoma of the skin,
             cervical carcinoma in situ or thyroid carcinoma.

          7. Current active second primary malignancy, other than skin carcinoma (basal or squamous
             cell carcinoma) or differentiated thyroid carcinoma.

          8. History of allergic reactions or known or suspected hypersensitivity attributed to
             compounds of similar chemical or biologic composition to tivozanib.

          9. Patients with uncontrolled intercurrent illness including, but not limited to, ongoing
             or active infection requiring systemic therapy (see exceptions below), or psychiatric
             illness/social situations that would limit compliance with study requirements

               -  Human immunodeficiency virus (HIV)-infected patients on effective anti-
                  retroviral therapy with undetectable viral load within 6 months are eligible for
                  this trial.

               -  For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV
                  viral load must be undetectable and on suppressive therapy, if indicated.

               -  Patients with a history of hepatitis C virus (HCV) infection must have been
                  treated and cured. For patients with HCV infection who are currently on
                  treatment, they are eligible if they have an undetectable HCV viral load.

         10. Significant cardiovascular disease, including: Active clinically symptomatic left
             ventricular failure, uncontrolled hypertension, myocardial infarction, severe angina,
             or unstable angina within 6 months prior to administration of first dose of study
             drug, history of serious ventricular arrhythmia, cardiac arrhythmias requiring
             anti-arrhythmic medications.

         11. Uncontrolled hypertension, i.e., blood pressure (BP) of >= 180/95; patients who have a
             history of hypertension controlled by medication must be on a stable dose (for at
             least one month) and meet all other inclusion criteria.

         12. Significant hematologic, gastrointestinal, thromboembolic, vascular, bleeding, or
             coagulation disorders.

         13. GI Bleeding (e.g., esophageal varices or ulcer bleeding) within 12 months. (Note: For
             patients with a history of GI bleeding for more than 12 months or assessed as high
             risk for esophageal variceal by the Investigator, adequate endoscopic therapy
             according to institutional standards is required.)

         14. Clinically meaningful ascites defined as ascites requiring non-pharmacologic
             intervention (e.g., paracentesis) to maintain symptomatic control, within 6 months
             prior to the first scheduled dose. Subjects on stable doses of diuretics for ascites
             for >= 2 months are eligible.

         15. Main portal vein thrombosis (Vp4) as documented on imaging. (VP4 is defined as portal
             vein thrombosis in the main trunk of the portal vein or a portal vein branch
             contralateral to the primarily involved lobe (or both).)

         16. Complex biliary obstruction requiring bile duct stents at more than one level of the
             biliary tree or external biliary drainage.

         17. Recurrent episodes of cholangitis (>1) in the preceding 3 months prior to enrollment.

         18. Therapeutic anti-coagulation or anti-platelet therapy with the exception of low
             molecular weight heparin or aspirin.

         19. Pregnant or lactating women. Pregnant women are excluded from this study because based
             on findings in animals and its mechanism of action, tivozanib can cause fetal harm
             when administered to a pregnant woman. In animal reproduction studies, administration
             of tivozanib to pregnant rats caused adverse developmental outcomes including embryo-
             fetal mortality. Because there is an unknown but potential risk for adverse events in
             nursing infants secondary to treatment of the mother with tivozanib, breastfeeding
             should be discontinued if the mother is treated with tivozanib. These potential risks
             may also apply to other agents used in this study.

         20. Treatment with systemic hormonal therapy within 3 weeks prior to start of protocol
             therapy, with the exception of:

               -  Hormonal therapy for appetite stimulation or contraception

               -  Nasal, ophthalmic, inhaled and topical steroid preparations

               -  Oral replacement therapy for adrenal insufficiency

               -  Low-dose maintenance steroid therapy (equivalent of prednisone 10 mg/day) for
                  other conditions

               -  Hormone replacement therapy
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Jonathan M Hernandez, M.D., (240) 409-8860, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT04645160

Organization ID

210006

Secondary IDs

21-C-0006

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)


Study Sponsor

Jonathan M Hernandez, M.D., Principal Investigator, National Cancer Institute (NCI)


Verification Date

December 9, 2020